DARE
Daré Bioscience, Inc.
There isn't enough reported data to score DARE yet.
DARE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
DARE's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
DARE PE Valuation
DARE has no meaningful PE right now: it lost money over the past year.
DARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DARE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
DARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.80 | +$1.35 |
| Q1 2026 | -$1.05 | -$0.87 |
| Q4 2025 | -$1.34 | -$0.82 |
| Q3 2025 | -$1.88 | -$1.17 |
| Q2 2025 | -$2.15 | -$0.91 |
| Q1 2025 | -$0.18 | +$3.78 |
| Q4 2024 | -$0.52 | +$3.68 |
| Q3 2024 | -$0.71 | +$4.93 |
DARE is still losing money, but far less than before: $0.80 per share over the past year, against $11.64 at its worst in late 2019.
DARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $152.5K | +500% |
| Q3 2025 | $2.3K | -95% |
| Q1 2025 | $25.4K | +173% |
| Q3 2024 | $41.7K | -96% |
DARE's revenue has slid since its 2022 peak: $187,546 last quarter, down 986% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1583% | N/A |
| Q1 2026 | -1967% | +16050 points |
| Q4 2025 | -144% | N/A |
| Q3 2025 | -162341% | -151112 points |
| Q1 2025 | -18017% | +46727 points |
| Q3 2024 | -11229% | -10389 points |
| Q2 2024 | -32799% | N/A |
| Q1 2024 | -64744% | N/A |
DARE's operating margin was −1583% last quarter, up 16434 points from the same quarter a year ago.
DARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -$1.6M |
| Q1 2026 | -$5.5M | +$107.2K |
| Q4 2025 | $1.2M | -73% |
| Q3 2025 | -$616.8K | +$5M |
| Q2 2025 | -$5.3M | -142% |
| Q1 2025 | -$5.6M | +$1.2M |
| Q4 2024 | $4.7M | +$13.4M |
| Q3 2024 | -$5.6M | +$2.4M |
DARE has burned cash in most quarters: −$12M over the past year, against −$12M the year before.
DARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +367K shares |
| 1 year | +70% | +6.1M shares |
| 3 years | +109% | +7.8M shares |
| 5 years | +466% | +12.3M shares |
DARE has 15M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q4 2024 | — |
DARE Net Leverage
DARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.6 | Oversold |
DARE's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
DARE PE vs Healthcare Sector
DARE has no meaningful PE right now: it lost money over the past year.
DARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 11% below |
| 20 week MA | $1.02 | 37% below |
| 50 week MA | $1.60 | 60% below |
| 100 week MA | $2.11 | 70% below |
| 200 week MA | $4.43 | 86% below |
DARE is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
DARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $16.9 | +72% |
| 2021 | $16.9 | $24.8 | +47% |
| 2022 | $24.8 | $10.4 | -58% |
| 2023 | $10.4 | $3.71 | -64% |
| 2024 | $3.71 | $3.27 | -12% |
| 2025 | $3.27 | $2.15 | -34% |
| 2026 YTD | $2.15 | $0.64 | -70% |
DARE has finished four years in a row lower, and it's down 70% so far in 2026.